Pulse Biosciences Schedules Third Quarter 2020 Financial Results Conference Call for November 9, 2020
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced it will release its third-quarter 2020 financial results on November 9, 2020, after market close. This announcement comes ahead of a scheduled conference call with management at 1:30 PM PT to discuss the results. The company is advancing its Nano-Pulse Stimulation™ (NPS™) technology, with the CellFX® System awaiting regulatory approval for commercial use in treating various dermatologic conditions. The technology aims to provide innovative solutions for patient care while offering a utilization-based revenue model.
- Advancement of Nano-Pulse Stimulation technology.
- Expected initial commercial use of CellFX System for dermatologic conditions.
- Utilization-based revenue model across expanding clinical applications.
- CellFX System and NPS technology are still for investigational use only.
- Regulatory approval for commercial use is pending.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter 2020 after market close on Monday, November 9, 2020. Company management will host a corresponding conference call beginning at 1:30pm PT.
Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX® System will be the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. To learn more please visit www.pulsebiosciences.com.
Caution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation technology are for investigational use only.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
